Related by context. All words. (Click for frequent words.) 82 single ascending dose 75 Phase 1a 73 Phase 2a trial 73 Phase Ia 73 dose escalation trial 73 Phase 2a clinical 72 Phase Ib 72 Phase 1b 71 ascending doses 71 dose escalation study 71 Phase 2b study 71 Phase IIa 70 Phase 1b trial 70 phase IIa 70 Phase 2a 70 dose escalation Phase 69 Phase III clinical 69 Phase IIa clinical 69 Phase 1a clinical 69 Phase 1b clinical 69 Phase IIb 69 Phase IIa trial 69 Phase IIb clinical 69 Phase Ib clinical 69 Phase 2b trial 68 Phase 2b clinical 68 phase Ib 68 phase IIb clinical 67 dose dose escalation 67 phase 2a 67 pharmacokinetics PK 67 Phase IIb trial 67 pivotal Phase III 67 Phase 2b 66 pharmacokinetic studies 66 Phase Ib study 66 viral kinetic 66 placebo controlled Phase 66 phase IIb 66 Phase IIa trials 66 dosing cohort 66 RDEA# 66 IIa trial 66 ascending dose 66 safety tolerability 65 phase IIa clinical 65 INCB# [001] 65 confirmatory Phase III 65 dose cohort 65 double blinded placebo 65 Phase IIb trials 65 randomized placebo controlled 65 placebo controlled 65 Phase #b/#a 65 dose escalation 65 dose escalation clinical 65 pharmacokinetic 65 Multiple Ascending Dose 65 multicenter Phase 65 Phase Ib II 65 placebo controlled randomized 64 Phase III 64 R#/MEM # 64 pivotal Phase 64 Phase IIB 64 phase IIb study 64 pharmacokinetic PK 64 dose cohorts 64 HGS ETR1 64 IDX# 64 safety tolerability pharmacokinetics 63 double blind placebo 63 PRX # 63 randomized Phase 63 multicenter randomized placebo controlled 63 ORMD 63 randomized Phase III 63 NOX E# 63 Phase IIIb clinical 63 blinded placebo controlled 63 pharmacodynamic PD 63 blind randomized placebo 63 registrational trial 63 Phase 2b clinical trials 63 treatment naive genotype 63 multicenter Phase II 63 masked placebo controlled 62 SCH # 62 Phase Ib clinical trials 62 RSD# oral 62 controlled dose escalation 62 alvespimycin 62 Androxal TM 62 blinded randomized placebo controlled 62 phase Ib clinical 62 Initiated Phase 62 Phase II 62 pharmacokinetic PK study 62 CIMZIA TM 62 controlled multicenter 62 initiate Phase 62 NO# [002] 62 BRIM3 62 TMC# C# 62 clinical trial 62 forodesine 62 placebo controlled clinical 62 Sym# 61 Cloretazine R VNP#M 61 randomized Phase 2b 61 GetGoal Phase III 61 generation PNP inhibitor 61 tolerability 61 LibiGel Phase III 61 pharmacokinetic profile 61 MEK inhibitor 61 dose escalation phase 61 IIa clinical trial 61 pharmacodynamic effects 61 MEND CABG 61 Phase III pivotal 61 PEG PAL 61 Laquinimod 61 Randomized Phase 61 confirmatory Phase 3 61 phase IIb trial 61 initiate Phase IIa 61 GLP toxicology studies 61 Phase 1b dose escalation 61 PSN# [002] 61 Phase 2a clinical trials 61 Initiate Phase 61 double blinded randomized 61 administered subcutaneously 61 urocortin 2 61 IND enabling 61 Dose escalation 61 glufosfamide 61 Phase IIIb 61 Phase #b/#a trial 61 lomitapide 61 maximally tolerated dose 61 elotuzumab 61 ganetespib 60 NGX# 60 MEND CABG II 60 label dose escalation 60 CR# vcMMAE 60 Fx #A 60 dosing cohorts 60 initiate Phase 2b 60 Pharmacokinetics PK 60 pivotal bioequivalence 60 AIR CF1 60 SUCCEED trial 60 multicenter randomized double 60 TMC# [002] 60 RG# [001] 60 dyskinesia PD LID 60 PDE4 inhibitor 60 II Clinical Trial 60 cannabinor 60 pharmacodynamics 60 Board DSMB 60 VICTOR E1 60 Phase III clinical trials 60 IIa clinical 60 mcg dose 60 oral rivaroxaban 60 placebo controlled Phase III 60 pharmacokinetics 60 desvenlafaxine succinate 60 pomalidomide 60 HCD# [002] 60 active comparator 60 tolerated dose MTD 60 APEX PD 60 ongoing Phase 1b 60 preclinical efficacy 60 multicenter phase 60 MEK inhibitor RDEA# 60 Phase #/#a 60 celgosivir 60 Plicera 60 oral prodrug 60 Prodarsan ® 60 initiate Phase IIb 60 pharmacodynamic profile 60 randomized double 60 GALNS 60 #mg QD [002] 60 blind placebo 60 PRTX 60 ADVANCE PD 60 Elagolix 60 IND submission 60 registrational 60 PXD# 60 teriflunomide 60 evaluating tivozanib 60 brivaracetam 60 Prodarsan 60 HCV SPRINT 59 IIa trials 59 pharmacodynamic 59 oral ridaforolimus 59 Phase IIa clinical trials 59 safety tolerability pharmacokinetic 59 pharmacokinetic PK profile 59 randomized multicenter 59 ISIS # 59 GAMMAGARD 59 CEQ# 59 relapsed refractory multiple myeloma 59 QLT# 59 PS# [001] 59 trodusquemine 59 blinded randomized 59 HGS# 59 Traficet EN 59 CK # 59 teduglutide 59 transcriptase inhibitor NNRTI 59 DermaVir Patch 59 Phase 2b randomized 59 orally bioavailable 59 randomized controlled Phase 59 nitazoxanide 59 investigational oral 59 Phase #b/#a clinical 59 Phenoptin 59 XL# [003] 59 pharmacokinetic pharmacodynamic 59 initiate Phase 1b 59 albinterferon alfa 2b 59 HGS ETR2 59 Randomized Phase II 59 mg BID 59 ANCHOR trial 59 virus HCV protease inhibitor 59 thorough QT 59 CRLX# 59 SILENOR TM 59 Triolex 59 BCX# 59 tanespimycin 59 Ostarine 59 PRECiSE 59 pharmacokinetic parameters 59 placebo controlled dose escalation 59 PRT# 59 polymerase inhibitor 59 Phase III placebo controlled 59 albiglutide 59 trastuzumab emtansine T DM1 59 Alzhemed TM 59 Phase III confirmatory 59 fosbretabulin 59 randomized #:# 59 nucleotide analog 59 JAK inhibitor 59 PEG Interferon lambda 59 Bezielle 59 BRIM2 59 Hsp# Inhibitor 59 Ozarelix 59 treatment naïve genotype 59 AZILECT R 59 NOXAFIL Oral Suspension 59 Spiegelmer ® 59 designated HVTN 58 GLPG# 58 ataluren 58 CG# [003] 58 budesonide foam 58 dextofisopam 58 ADX# 58 REG2 58 multicenter randomized 58 mg dose 58 Parkinson disease levodopa induced 58 lintuzumab SGN 58 ruxolitinib 58 RE SURGE 58 Phase III randomized 58 randomized controlled 58 velafermin 58 sapacitabine 58 CTA# Injection 58 multicentre randomized 58 APTIVUS 58 torezolid phosphate 58 mg/m2 cohort 58 subcutaneous dose 58 TBC# 58 multicentre randomized double 58 pramlintide 58 Blinatumomab 58 rALLy clinical trial 58 bicifadine 58 nab paclitaxel 58 Capesaris 58 mGluR5 negative 58 eosinophilic asthma 58 oral methylnaltrexone 58 REVIVE Diabetes 58 multicenter placebo controlled 58 clinical pharmacology studies 58 Phase Ib IIa 58 mertansine 58 non nucleoside inhibitor 58 randomized Phase IIb 58 TG# [001] 58 evaluating RDEA# 58 PHX# 58 Phase 1b clinical trials 58 Phase 58 refractory CLL 58 SPIRIT FIRST 58 PRE SURGE 58 adecatumumab MT# 58 investigational drug 58 GOUT 58 IMC A# 58 investigational compound 58 confirmatory clinical 57 Zerenex 57 DSMB 57 mGluR5 NAM 57 IMGN# 57 Phase IIb Trial 57 Phase III Clinical Trial 57 elagolix 57 multicenter Phase III 57 ZYBRESTAT 57 blind randomized 57 selective androgen receptor modulator 57 Amigal 57 RSD# 57 ILLUMINATE 57 AEZS 57 multicenter clinical 57 SAR# [004] 57 subcutaneously administered 57 NLX P# 57 huN# DM1 57 PF # [001] 57 palifosfamide Zymafos TM 57 PROPEL trial 57 OPT CHF 57 oral renin inhibitor 57 AEGR 57 Amrubicin 57 #mg/m# [001] 57 Phase III trials 57 midstage clinical 57 Phase III randomized controlled 57 randomized crossover 57 antibody MAb 57 crizotinib PF # 57 unblinded 57 AEG# 57 generation NNRTI 57 axitinib 57 LUX Lung 57 HuMax EGFr 57 evaluating mipomersen 57 prospective observational 57 Tasimelteon 57 BLOOM Behavioral modification 57 AP# [003] 57 mg kg dose 57 Phase III Pivotal 57 lintuzumab 57 XOMA 3AB 57 ofatumumab 57 ANAVEX #-# [003] 57 Dacogen injection 57 Sapacitabine 57 PD LID 57 refractory AML 57 multinational multicenter randomized 57 lead Aganocide compound 57 Dextofisopam 57 elacytarabine 57 Dapagliflozin 57 diabetic neuropathic pain 57 HuMax CD4 57 Ophena TM 57 TACI Ig 57 BLA submission 57 Omacetaxine mepesuccinate 57 Forodesine HCl 57 blind placebo controlled 57 COU AA 57 dirucotide 57 ATL# [001] 57 CORT # 57 Actilon 57 VNP#M 57 Tanespimycin 57 ELACYT 57 Pivotal Phase III 57 LEXIVA r 57 posaconazole 57 tasimelteon 57 sulodexide 57 receptor tyrosine kinase inhibitor 57 Menerba 57 unique alkylating agent 57 randomized clinical 57 perifosine 57 generation purine nucleoside 57 YONDELIS 57 dose pharmacokinetic 57 midstage trials 57 APPRAISE 57 IMA# 57 HCV RESPOND 2 57 MERLIN TIMI 57 immunogenicity 57 R# #mg BID 57 phase IIb III 57 Quinamed 57 Triapine 57 Maximum Tolerated Dose MTD 57 compound INCB# 57 recurrent glioblastoma multiforme 57 AVE# 57 HCV infected 57 orally administered 57 stated Michelle Berrey 57 Pharmacokinetic 57 IMP# 56 ACTEMRA TM 56 preclinical pharmacokinetic 56 nalbuphine ER 56 allosteric modulator NAM 56 BLA filing 56 Archexin 56 Phase #/#a trial 56 CCR5 antagonist 56 prospective randomized placebo 56 blind multicenter 56 μg dose 56 LymphoStat B TM 56 HCV nucleotide polymerase inhibitor 56 azilsartan medoxomil 56 Phase 2a Study 56 mcg kg 56 Bicifadine 56 preclinical 56 Tarceva TM 56 TRO# 56 maturation inhibitor 56 generation Hsp# inhibitor 56 intermittent dosing 56 eniluracil 56 CoFactor 56 oral deforolimus 56 histone deacetylase HDAC inhibitor 56 FOLOTYN ® 56 initiated Phase Ib 56 Antiviral Activity 56 immunosuppressive compound 56 cancer neuroendocrine tumor 56 Darusentan 56 hGH CTP 56 multicenter randomized Phase 56 anti leukemic 56 glatiramer acetate 56 confirmatory pivotal 56 mg RDEA# 56 JAK2 inhibitor 56 Corlux 56 assessing T DM1 56 Phase IIb clinical trials 56 randomized blinded 56 resminostat 56 riociguat 56 telaprevir dosing 56 label multicenter 56 plus Copegus R 56 Phase IIb III 56 pharmacodynamics PD 56 satraplatin Phase 56 Omacetaxine 56 NXL# 56 Phase #/#a clinical 56 SYMMETRY trial 56 Phase III HEAT 56 REGN# 56 LCP Tacro 56 HCV NS5B polymerase 56 CRx 56 EQUATE OB 56 Dasatinib 56 prospective multicenter randomized 56 alvimopan 56 Posiphen 56 prospective randomized multicenter 56 dimebon 56 ZYBRESTAT fosbretabulin 56 SparVax TM 56 CHAMPION PCI 56 Phase III ALLEGRO 56 sodium glucose cotransporter 56 ponatinib 56 European Sepsis Trial 56 enzastaurin 56 VIRAMUNE XR 56 oral formulation 56 #mg/m# [002] 56 mg TID 56 prospectively defined 56 MLN# 56 Maximum Tolerated Dose 56 vidofludimus 56 dexpramipexole 56 Cloretazine ® 56 KRN# 56 Aurora kinase inhibitor 56 Valortim R 56 rindopepimut 56 unblinding 56 telaprevir dosed 56 denufosol 56 avosentan 56 ritonavir boosted 56 integrase inhibitor 56 docetaxel chemotherapy 56 Cloretazine 56 PNP inhibitor 56 QD dosing 56 PRIMO CABG 56 drug pipeline TAFA# 56 Phase 2b Clinical Trial 56 GLYX 56 MGCD# [001] 56 EDEMA3 trial 56 tolerability profile 56 alagebrium 56 randomized 56 Motesanib 56 relapsed MM 56 preclinical studies 56 XL# SAR# 56 Cimzia TM 56 ritonavir boosting 56 NVA# 56 cetrorelix 56 Diamyd R 56 laquinimod 56 Zoraxel 56 Phase 2b monotherapy 56 oral sapacitabine 56 atazanavir ritonavir 56 Phase III multicenter 56 primary hypercholesterolemia 56 mapatumumab 56 nonclinical studies 56 deforolimus 56 AVADO 56 ThGRF 56 huC# DM4 56 COSIRA trial 56 dextromethorphan quinidine 56 AZD# 56 LEVADEX 56 monotherapy 56 8mg/kg 56 TELINTRA 56 Pimavanserin 56 CCR5 mAb 56 HIV uninfected 56 NP2 Enkephalin 56 Testosterone MDTS ® 56 Valortim 56 LymphoStat B Phase 56 enoximone 56 PDX pralatrexate 56 multicenter 55 voreloxin 55 GSK# [001] 55 3 registrational trial 55 custirsen 55 tgAAC# 55 LB# [003] 55 label multicenter randomized 55 DSMB recommended 55 dacetuzumab 55 humanized anti 55 valopicitabine 55 Onrigin 55 NEBIDO 55 omecamtiv mecarbil 55 Diamyd ® 55 EOquin 55 Protexia R 55 CLL8 55 dose limiting toxicities 55 Phase IIA 55 EDEMA3 55 PREZISTA r 55 Pivotal Phase 55 CIMZIA ™ 55 neratinib 55 Sorafenib HCC Assessment 55 favorable pharmacokinetic profile 55 Empatic 55 XL# anticancer compounds 55 HspE7 55 RRMS patients 55 evaluable subjects 55 LAB CGRP 55 RSD# iv 55 novel histone deacetylase 55 CLIRS trial 55 eprotirome 55 phase IIIb 55 PEG SN# 55 Apoptone 55 lorvotuzumab mertansine 55 multicentre 55 dacetuzumab SGN 55 mg doses 55 OncoVEX GM CSF 55 TEMSO 55 randomized #:#:# 55 tolerability profiles 55 ApoB SNALP 55 AIR CF2 55 novel VDA molecule 55 carfilzomib 55 orally dosed 55 APTIVUS r 55 CYT# 55 TELCYTA 55 PEARL SC 55 vicriviroc 55 placebo controlled clinical trials 55 Phase lll 55 venlafaxine ER 55 subcutaneous PRO 55 anticancer compound 55 XIENCE V Stent System 55 ELND# 55 refractory chronic lymphocytic 55 tarenflurbil 55 investigational protease inhibitor 55 XL# XL# XL# XL# 55 BENLYSTA ™ 55 liposomal formulation 55 DLTs 55 PANVAC VF 55 subcutaneous formulation 55 plus dexamethasone 55 cathepsin K inhibitor 55 IMC #B 55 Phase 2b Trial 55 Anturol TM 55 AQ4N 55 sNDA submission 55 HDAC Inhibitor 55 ANA# 55 tezampanel 55 Tamibarotene 55 Trial Evaluating 55 Anthim 55 clinical trials Multikine 55 Panzem R NCD 55 ARRY 55 Zenvia ™ 55 Zenvia TM 55 GATTEX ™ 55 CAMMS# 55 PEGPH# 55 Mipomersen 55 Genasense oblimersen sodium Injection 55 CATIE AD 55 PA# [002] 55 preclinical toxicology 55 Aptivus ® 55 INCB# [002] 55 UVIDEM 55 Randomized Double blind 55 eltrombopag 55 LCP AtorFen 55 BENICAR HCT 55 cilengitide 55 DB# [003] 55 AZX# 55 Phase 2a Trial 55 NU# [001] 55 Enzastaurin 55 SRT# [003] 55 bevirimat Study 55 bapineuzumab AAB 55 TASKi2 55 SUVN 55 initiate multicenter 55 intravenous dosing 55 aflibercept 55 MAP# 55 CA4P 55 visilizumab 55 mg QD 55 immunotherapeutic agent 55 Vascular Disrupting Agent 55 Azixa 55 HCV protease inhibitor 55 BiTE R 55 interferon gamma 1b 55 Protexia ® 55 Annamycin 55 GFT# 55 GSK# [002] 55 PEG IFN 55 dosage regimens 55 prospective randomized controlled 55 ozarelix 55 randomized multicentre 55 Phase IIb Clinical Trial 55 SAR# [002] 55 Genasense ® oblimersen 55 MGd 55 oral FTY# 55 RiVax 55 Adalimumab 55 highly immunogenic 55 Triapine R 55 blinatumomab 55 TOLAMBA 55 GATTEX ® 55 Marqibo 55 HPTN 55 dependent kinase inhibitor 55 bile duct tumor 55 NDA submission 55 MAA submission 55 neurogenic orthostatic hypotension 55 thymalfasin 55 Pegasys plus Copegus 55 trivalent seasonal influenza VLP 55 PPAR gamma agonist 55 paclitaxel poliglumex 55 BAY #-# 55 metaglidasen 55 bendamustine 55 Phase III Clinical Trials 55 Tyrima 55 decitabine 55 Azedra 55 DDP# 55 dose titration 55 trastuzumab DM1 T DM1 55 BIM #A# 55 davunetide intranasal AL 55 PARTNER Trial 55 antiretroviral naive 54 Carfilzomib 54 DU #b 54 4mg/kg 54 ICA # 54 EMPOWER ™ 54 INSPIRE Trial Phase III 54 Androxal ® 54 ALKS 54 vascular disrupting agent 54 Perifosine 54 LymphoStat B belimumab 54 rNAPc2 54 TG MV 54 Phase III psoriasis 54 clinical trials 54 PROVENGE sipuleucel T 54 randomized multicenter Phase III 54 relapsed refractory AML 54 vivo preclinical 54 Diabetic Macular Edema 54 RGB # 54 Allovectin 7 54 alicaforsen enema 54 CDK inhibitor 54 AeroLEF TM 54 subanalysis 54 evaluating bafetinib 54 Vicriviroc 54 relapsing remitting multiple sclerosis 54 Solulin 54 ocrelizumab 54 LIALDA 54 nucleoside analog 54 Trizytek 54 statistically significant efficacy 54 Serdaxin ® 54 ALTU 54 AERAS-#/Crucell Ad# 54 antiviral efficacy 54 IV bolus 54 selective modulator 54 MIST II 54 Hedgehog pathway inhibitor 54 daily subcutaneous injections 54 #mg dose [003] 54 BOLDER II 54 EVIZON 54 pitavastatin 54 MAXY alpha 54 Phase IIIb study 54 oral nucleoside analogue 54 primary efficacy endpoint 54 docetaxel Taxotere R 54 Phase III metastatic melanoma 54 Oral Fingolimod 54 Aurexis 54 6R BH4 54 fluticasone furoate 54 refractory acute myeloid 54 tezampanel NGX# 54 PFO migraine 54 TMC# [001] 54 metastatic castration resistant 54 solithromycin 54 PRIMO CABG2 54 DP b# 54 budesonide MMX 54 Lixisenatide 54 PMX # 54 Thorough QT 54 clinical trials Archexin ® 54 Golimumab 54 SPC# [001] 54 PS# DARA 54 mipomersen 54 ulimorelin 54 CBLB# 54 q#h 54 pegylated interferon alpha 54 metastatic HRPC 54 Maribavir 54 lorcaserin Phase 54 Denufosol 54 Proellex TM 54 sunitinib malate 54 REMUNE R 54 AKT inhibitor 54 ISTODAX 54 secondary efficacy endpoints 54 By JENNIFER LEARN 54 Prostate Lung Colorectal 54 Virulizin ® 54 systemically administered 54 ITMN 54 Imprime PGG 54 IL# PE#QQR 54 investigational pan BCR 54 KRAS mutations occur 54 refractory multiple myeloma 54 CCX# 54 MDS AML 54 volociximab 54 MOR# 54 VEGF Trap 54 initiate Phase Ib 54 prospective multicenter 54 nucleoside tide 54 inhaled formulation 54 multicenter randomized controlled 54 metastatic renal cell carcinoma 54 IFN α 54 ALN VSP Phase 54 ASSERT trial 54 Peginterferon 54 antiviral activity 54 TRIOLEX 54 hypoxia activated prodrug 54 PREOS R 54 Initiates Phase II 54 Phase III Trial 54 unblind 54 Androxal 54 PREOS 54 baminercept 54 label multicenter Phase 54 efficacy endpoint 54 Aclidinium 54 COMFORT II 54 galiximab 54 N acetylgalactosamine 6 54 CLORETAZINE TM VNP#M 54 randomized controlled clinical 54 randomized controlled multicenter 54 adalimumab 54 AZOR 54 evaluating T DM1 54 comparing alemtuzumab 54 long acting muscarinic 54 mg/m2/day 54 pharmacokinetics pharmacodynamics 54 dasatinib Sprycel ® 54 Primary endpoints 54 INCB# [003] 54 AVN# [001] 54 Tezampanel 54 H#N# VLP vaccine 54 VITAL Trial 54 opioid induced bowel dysfunction 54 Luveniq 54 synthetic retinoid 54 PI3K/Akt pathway inhibitor 54 trabedersen 54 cutaneous T 54 Oglemilast 54 JZP 54 Cethromycin 54 Valortim ® 54 AGILECT R 54 MB# [004] 54 Glufosfamide 54 ALN RSV# 54 QNEXA 54 EURIDIS 54 ribavirin RBV 54 NASDAQ CXSP announced 54 IIb clinical trial 54 Eniluracil 54 GRN# 54 evaluating satraplatin 54 mg/m2 dose 54 HER2 positive metastatic breast 54 relapsed myeloma 54 safinamide 54 melphalan prednisone 54 ABSORB clinical 54 ALISTA 54 Ocrelizumab 54 Exelixis compounds 54 BCR ABL inhibitor 54 Aflibercept 54 #.#mg/kg [002] 54 TLK# 54 MAGE A3 ASCI 54 NN# [001] 54 TKB# 54 PKC# 54 MIRCERA 54 LY# [003] 54 JAK1 54 rALLy trial 54 Pivotal Trial 54 Kahalalide F 54 demonstrated antitumor activity 54 octreotide implant 54 DCCR 54 Naproxcinod 54 Phase 2b Study 54 rilonacept 54 eliglustat tartrate 54 abiraterone acetate 54 tolerability pharmacokinetics 54 Phase 2a Clinical Trial 54 orally administered inhibitor 54 Genz # 54 investigational humanized monoclonal antibody 54 inhaled AAT 54 cell lymphoma CTCL 54 REVLIMID lenalidomide 54 MORAb 54 Protease Inhibitor 54 registrational Phase 54 placebo controlled studies 54 DASISION 54 lixisenatide 54 ZOLINZA 54 reversible inhibitor 54 brentuximab vedotin SGN 54 Blind Placebo Controlled Trial 54 GRN#L 54 darusentan 54 TO AVOID PREGNANCY WHILE 54 metreleptin 54 multicenter multinational 54 acyclovir Lauriad R 53 pertuzumab 53 bolus injection 53 methotrexate MTX 53 Zenvia Phase III 53 pharmacokinetic profiles 53 virus HCV infection 53 PEGylated anti 53 RG# ITMN 53 sodium Injection 53 ARIKACE 53 Clinical Study 53 mitogen activated ERK kinase 53 trial evaluating PRX# 53 #mg/day [002] 53 ABSORB trial